AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01789463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self rehabilitation plus physiotherapy
Study NCT00573950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
Study NCT01388374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Other, care provided by Nurse Practitioners
Description: Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
Study NCT04303884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Pembrolizumab administration at a fix dose of 200 mg every 3 weeks
Study NCT03516539 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group ML
Description: Mcgrath videolaryngoscope
Study NCT02580773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prophylactic anticoagulation ( INNOHEP®)
Description: subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
Study NCT02580773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curative anticoagulation ( INNOHEP®)
Description: subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
Study NCT02026973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study NCT03516539 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group DL
Description: Macintosh laryngoscope
Study NCT02026973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Study NCT02026973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03913377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Subjects' own habitual spectacles
Study NCT01828125 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Study NCT03913377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE OASYS®1-Day with HydraLuxe™ Technology
Description: Test 1
Study NCT03196258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Description: Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
Study NCT04018404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FRI CLINICAL PROGRAM
Description: University Le Bonheur Pediatric Specialists and Le Bonheur Community Health and Well-Being, Maternal Child Department, have started the Family Resilience Initiative (FRI) in the ULPS General Pediatrics Clinic. This clinical program screens children 9 months to less than five years of age for ACES and SDH at the time of presentation for well child checks. There are two outreach coordinators who screen and enroll children attending clinic for a well-child check during morning clinics 3 to 4 days per week. Children with positive screens for ACES and/or SDH, and their adult caregivers, receive community resource referrals with warm handoffs to vetted organizations. In addition, if indicated, psychological services are offered for children based upon the presence of one or more of ACEs and current health and behavioral problems.
Study NCT02278809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Movie Models
Description: The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)~After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring...
Study NCT02736123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab - Arm A
Description: Nivolumab will be given during the induction phase of the study for 6 weeks. This is followed by surgery. Then maintenance therapy (after recovery from surgery).
Study NCT02736123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab - Arm B
Description: Nivolumab + ipilimumab during the induction phase of the study for 6 weeks. This is followed by surgery (week 6-8+). Then maintenance therapy will be initiated for up to one year from study drug initial administration ((after recovery from surgery).
Study NCT00042874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study NCT00042874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00042874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00042874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00042874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02105272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-1085EL ophthalmic solution
Study NCT02105272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Study NCT03135236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training
Description: Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
Study NCT02026973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatostatin
Study NCT02167152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic preconditionin
Description: Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
Study NCT02167152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic preconditionin
Description: Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine replacement therapy - transdermal nicotine patch
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT03600883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotorasib
Description: Characterize the pharmacokinetics (PK) of sotorasib following administration as an oral Tablet formulation
Study NCT03600883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti PD-1/L1
Description: Administered as an intravenous (IV) infusion
Study NCT03600883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered as an oral hydrochloride (HCI) syrup
Study NCT01592695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - transdermal nicotine patch
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
Study NCT01592695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored behavioral intervention
Description: Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
Study NCT01720667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam
Description: Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
Study NCT01720667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous phenobarbital
Description: Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.
Study NCT01304862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSMART-MH intervention
Description: Involves simulated interactions between participants and the virtual health care providers (avatars).
Study NCT01304862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational videos about healthy living
Description: 20 minute screen-based educational videos on topics about healthy living--nutrition, physical activity, and sleep hygiene.
Study NCT03683199 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhinoplasty
Description: The cleft lip rhinoplasty will be performed under general anesthesia.~1: 100,000 epinephrine will be infiltrated in the columellar incision and in the septum.~Open approach rhinoplasty will be used. A step ladder incision placed at the patient's columella, and continued with infra-cartilaginous incision.~The columellar skin flap along with the nasal tip skin will be dissected from the lower lateral cartilages.~Harvesting of the septal cartilage, to be used as spreader graft and columellar graft. Correction of the septal deviation.~Lengthening of the columella on the expense of the ala. Correction of the nasal tip by suturing techniques and by cartilage grafts.
Study NCT02563431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYSTAM - SP-ED
Description: * Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.~* Daily passive mobilisation of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)
Study NCT02563431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasling ER 15°Donjoy - 4P-ED
Description: * Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.~* A training of the patient and members of family on pathology, risk, use of material~* Daily passive mobilization of the upper member by a therapist.~* Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis.
Study NCT01701635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure intervention
Description: An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.
Study NCT01701635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
Study NCT02743754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
Study NCT02743754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
Study NCT04407507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
Study NCT02743754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Oxygen
Description: The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.
Study NCT01678690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine HCl Oral Formulation
Description: Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
Study NCT03811873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dual x-ray absorptiometry
Description: DEXA is a means of measuring bone mineral density (BMD) using spectral imaging. Two X-ray beams, with different energy levels, are aimed at the bones. Soft tissue absorption is subtracted out, then the bone mineral density (BMD) can be determined from the absorption of each beam by bone.
Study NCT04407507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days
Study NCT03811873 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vertebral Fracture Assessment
Description: Lumbar/thoracic spine x-ray and labs assessed for bone turnover markers.
Study NCT02323360 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions
Study NCT02323360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE
Study NCT02280083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A for Injection
Description: HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)
Study NCT02280083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01274260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
Study NCT01274260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (0.9%)
Description: The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
Study NCT03869892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil hydrochloride (S95005)
Description: Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.
Study NCT03869892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
Study NCT03869892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab experimental
Description: Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
Study NCT03466164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Program
Description: 8 week, 10-session course of mindfulness training
Study NCT05053542 — intervention group
Intervention type: PROCEDURE
Intervention: Enema
Description: Patients in the PBP group underwent a cleansing enema procedure with a solution of monosodium phosphate and disodium phosphate (EVAC enema 118 mL/bot, Purzer Pharmaceutical Co., Ltd) before hemorrhoidectomy, whereas patients in the non-PBP group skipped the procedure.
Study NCT03355664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACT
Description: Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24
Study NCT03584802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchanges
Description: The patient will initially receive Methylprednisolone bolus of 1g i.v. day 1, then 20 mg/day (or oral prednisone equivalent) for 21 days; and then he will have nine therapeutic plasma exchanges of 1.5x the estimated plasma volumes using albumin:saline (3:1) or fresh frozen plasma in case of an INR superior to 1.5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100 mg/kg). On days 7 and 15, the patient will receive rituximab 1 g i.v. on days 7 and 15 (after therapeutic plasma exchange and premedication); and intravenous immunoglobulin 0.5 g/kg/d on days 16 to 19.
Study NCT03584802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment of AE-IPF
Description: Conventional treatment of AE-IPF
Study NCT03355664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACT
Description: Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose primaquine at hour 24
Study NCT02753244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Based Cognitive Video Games Software
Description: Intendu FBT motion based cognitive video games software
Study NCT02753244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iPad Apps
Description: Commercially available iPad game applications
Study NCT02166372 — intervention group
Intervention type: OTHER
Intervention: Observation of natural course of Diabetes Mellitus Type 2
Study NCT03662243 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multicomponent reading and writing treatment
Description: Intervention procedures incorporated into the program include drilling on sight words to improve immediate recognition of common words; engaging in Multiple Oral Reading procedures to increase reading fluency; practicing oral spelling of sight words to improve spelling accuracy; generating written sentences to improve accurate spelling and use of written conventions (e.g., punctuation, capitalization); and summarizing and subsequently writing sentences about read material to establish strategies to enhance reading comprehension and promote written expression.
Study NCT00885001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short Arc Banding
Description: Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
Study NCT01230775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide retard
Description: Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.
Study NCT01230775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Week 1:~1. x1 tablet/d of placebo will be administered in week 1.~   Week 2~   Placebo:~2. x1 tablet/d of placebo will be administered in week 2.~Week 3 - Week 4~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/
Study NCT02873520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study NCT02873520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Study NCT02873520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Precision Cell Immunotherapy
Description: DC cell suspension (1×10\*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study NCT03749642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trazodone/gabapentin 2.5/25 mg
Description: The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.